CD8A and neoplasm: A simultaneous blockade of TIGIT and PD-1 was also investigated in a study by Chauvin et al., where it was shown to cause a 2.3-fold increase in tumor antigen-specific CD8+ T cells compared to IgG control, or either monotherapy [77].